About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
HALO - Halozyme Therapeutic...| Previous Close | $45.01 | Open | |
| Volume | 37 | Market Cap | 6.282B |
| Yield | Last Dividend |
| Halozyme Therapeutics, Inc. Announces Pr... | 02/24/21 |
| SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics... | |
| Halozyme Therapeutics, Inc. Announces Pr... | 02/23/21 |
| SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics... | |
| Halozyme Reports Fourth Quarter 2020 Res... | 02/23/21 |
| SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full y... | |
| Halozyme Therapeutics's Earnings: A Prev... | 02/22/21 |
| Halozyme Therapeutics (NASDAQ:HALO) releases its next round of earnings this Tuesday, February 23. Get the latest predictions in Benzinga's essential ... | |
| The Week Ahead In Biotech: J&J Vaccine A... | 02/20/21 |
| Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pa... | |
| Halozyme To Host Fourth Quarter And Full... | 02/10/21 |
| /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2020 on Tuesday, F... | |
| The Daily Biotech Pulse: Lilly COVID-19 ... | 02/10/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 M... | |
| The Daily Biotech Pulse: Novartis Misses... | 01/26/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abb... | |
| Halozyme Announces Janssen Receives FDA ... | 01/15/21 |
| SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) has received ... | |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO... | 01/05/21 |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Kenneth J. Kelley sold 5,000 shares of the firm???s stock in a transaction dated Monday, January 4t... | |
| Halozyme To Present Virtually At The 39t... | 01/04/21 |
| /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present ... | |
| Halozyme Raises Full Year 2020 Guidance | 11/23/20 |
| SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to ref... | |
| Horizon Therapeutics plc and Halozyme Th... | 11/23/20 |
| /PRNewswire/ -- Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and lice... | |
| Halozyme Therapeutics (NASDAQ:HALO) Pric... | 11/20/20 |
| Halozyme Therapeutics (NASDAQ:HALO) had its target price upped by Wells Fargo & Company from $39.00 to $60.00 in a research report report published on... | |
| The Daily Biotech Pulse: Kazia Jumps On ... | 11/18/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17) Aer... | |
| Halozyme Announces CHMP Recommends EU Ap... | 11/13/20 |
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (... | |
| The Daily Biotech Pulse: Urovant In M&A ... | 11/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX... | |
| Halozyme Announces Janssen Submission Of... | 11/12/20 |
| SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitte... | |
| The Daily Biotech Pulse: Lilly's COVID-1... | 11/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alco... | |
| Halozyme Announces Upcoming Data Present... | 11/05/20 |
| SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Develo... | |
| The Daily Biotech Pulse: Bluebird Bio Pl... | 11/05/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbo... | |
| The Daily Biotech Pulse: Alzheimer's Con... | 11/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 3) Bio-... | |
| 15 Stocks Moving In Monday's After-Hours... | 11/02/20 |
| Gainers Arista Networks (NYSE: ANET ) shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company ... | |
| $0.20 EPS Expected for Halozyme Therapeu... | 10/24/20 |
| Analysts expect that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will announce $0.20 earnings per share (EPS) for the current quarter, according to Zack... | |
| The Daily Biotech Pulse: Gilead Gets Ful... | 10/23/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Ami... | |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO... | 10/23/20 |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 12,000 shares of the company???s stock in a transaction that occurred on Tuesday... | |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO... | 10/22/20 |
| Wall Street analysts predict that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will report $60.00 million in sales for the current fiscal quarter, accord... | |
| Halozyme To Host THIRD Quarter 2020 Fina... | 10/22/20 |
| SAN DIEGO, Oct. 22, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third qu... | |
| Michael J. Labarre Sells 12,000 Shares o... | 10/21/20 |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 12,000 shares of Halozyme Therapeutics stock in a transaction that occurred on T... | |
| Brokerages Set Halozyme Therapeutics, In... | 10/21/20 |
| Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received a consensus recommendation of ???Buy??? from the fourteen research firms that are currently cov... | |
| Buy rating | 12/17/20 |
| Berenberg initiates coverage with Buy rating and announces Price Target of $50.00 | |
| Date | 2021-02-23 (AMC) | Est. (EPS/Rev.) | $0.53/ 120.16M |
| Actual (EPS/Rev.) | $0.50/ $121.70 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| ITM Options Only | Hao | 66.00 % | Subscribe |
| Momentum Stocks Only | Hao | 56.00 % | Subscribe |
| Burdeshaw Investing | Matthew Burdeshaw | 56.00 % | Subscribe |
| Symmetry Options | Symmetry Options | 33.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
